Lilly to pay $8bn for Loxo Oncology as cancer M&A soars
Eli Lilly, the US pharmaceuticals company, has agreed to buy Loxo Oncology for around $8bn, as big ticket consolidation in the drug sector continues apace.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: